Eli Lilly Shares Plunge 11% Amid Earnings Guidance Cut and Zepbound Sales Miss

Unknown Apr 02, 2026 950 Views

Eli Lilly & Co. (NYSE: LLY) shares continued to drop Thursday, declining 11% after the pharmaceutical giant posted first-quarter results that, while featuring strong revenue growth, were disappointing to investors with softer-than-expected sales of its best-selling weight loss drug Zepbound a...

Stay Ahead – Explore Now! RBL Bank Appoints Bhavin Lakhpatwala as Chief Financial Officer